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Introduction 
Coronary artery disease (CAD) is one of the leading causes of morbidity and 
mortality worldwide, despite of significant advances in its management and treatment1. 
Recent advancement in understanding the pathophysiology of CAD allows 
identifications of potential novel therapeutic targets that may improve clinical outcomes, 
especially in the patients who are treatment refractory or still experience poor outcome 
despite of receiving standards of care. It is well accepted now that inflammation plays a 
key role in the formation and destabilization of atherosclerotic plaques, leading to CAD 
clinical events such as myocardial infarction2.  
In addition to their well-known role as xenobiotic metabolizing enzymes, 
cytochrome P450 (CYP) enzymes are also part of the arachidonic acid metabolism 
pathway, which produces metabolites that regulate numerous downstream cellular and 
physiologic processes. Most notably, the cytochrome P450 (CYP) epoxygenase 
enzymes CYP2J and CYP2C catalyze the epoxidation of arachidonic acid to 
epoxyeicosatrienoic acids (EETs), which exhibit potent vasodilatory and anti-
inflammatory effects in preclinical models3. However, they are rapidly hydrolyzed to less 
bioactive dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH). In 
parallel, CYP4F and CYP4A 𝜔-hydroxylases generate 20-hydroxyeicosatetreanoic acid 
(20-HETE), which is a potent vasoconstrictor and has pro-inflammatory effects4. 
Increasing EET levels by inhibiting its hydrolysis and inhibition of 20-HETE biosynthesis 
have demonstrated cardioprotective effects beyond just maintaining vascular tone. 
Some suggested mechanisms include inhibiting endothelial activation and leukocyte 
adhesion via attenuation of nuclear factor-kappaB activation, inhibiting hemostasis, 
protecting against myocardial ischemia–reperfusion injury, and promoting endothelial 
cell survival via modulation of multiple cell signaling pathways5. 
An accumulating body of preclinical evidence has demonstrated the 
cardiovascular protective effects of EETs5. Lower 14,15-EET:DHET ratios (higher sEH 
metabolic function) and lower EET levels are associated with vascular dysfunction and 
pro-inflammatory phenotypes predictive of poor prognosis6. Association between 
functional polymorphisms in genes responsible for EET biosynthesis (CYP2C8, CYP2J2) 
or EET hydrolysis (EPHX2) and CAD risk has also been reported3. This inter-individual 
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variability suggests that the subset of CAD patients with low EET levels may be 
predisposed to poor CV outcomes and may benefit from interventions that promote 
biological effects of EETs3. Plasma 20-HETE levels were found to be associated with 
endothelial dysfunction, which could be linked to poor CV outcomes6. Unfortunately, 
due to the technical complexity of quantifying EET and 20-HETE levels, which are 
present at low concentrations in blood and tissue, these metabolites are not commonly 
quantified on traditional metabolomic or eicosanoid analytical platforms. As a 
consequence, major gaps in knowledge surrounding the biological and therapeutic 
importance of CYP-derived eicosanoids in human CAD exist. 
Before we can translate this information to clinical application, we need to fill the 
knowledge gap by establishing the direct association of metabolic function of the CYP 
epoxygenase/EET pathway and cardiovascular outcomes. The main objective of this 
study is to evaluate the relationship between the function of CYP-derived EETs 
metabolic pathway and major cardiovascular outcomes in patients with stable CAD. This 
will provide insight into whether metabolites involved in the pathway can be used as 
biomarkers in predicting prognosis of CAD. In addition, it will offer insight into which 
subset of the patient population will most likely to respond and benefit from novel 
therapies in development that manipulate these pathways.  
In patients with stable coronary artery disease (CAD), low-dose aspirin is 
indicated to suppress cyclooxygenase-mediated thromboxane (TxA2) biosynthesis in 
platelets and reduce risk of major adverse cardiovascular events (MACE)7. However, 
approximately 30% of TxA2 is produced by extraplatelet sources8, which may contribute 
to CAD progression. Preclinical studies have demonstrated that in addition to its effects 
in platelet activation, TxA2 also has pro-inflammatory effects in the cardiovascular 
system that promote the development, growth and destabilization of atherosclerotic 
plaques9. On the other hand, another regulator of platelet functions, prostacyclin (PGI2), 
has potent vasodilatory and anti-inflammatory effects7. The clinical implications, 
however, remain unclear. As part of a secondary exploratory analysis of this study, we 
will also investigate the association between stable biomarkers of TxA2 and PGI2 and 
cardiovascular outcomes in patients with stable CAD.  
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Methods 
Study Population 
This is retrospective observational study. A cohort of 139 adult patients with 
angiographically confirmed CAD (defined as ≥50% stenosis in one or more major 
coronary arteries), were identified in the University of North Carolina (UNC) Cardiac 
Catheterization Laboratory from October 2007 to November 201010. Exclusion criteria 
included pregnancy, atrial fibrillation, left-ventricular systolic dysfunction (ejection 
fraction ≤35%), current use of long-acting nitrates or insulin, active autoimmune disease, 
history of severe aortic stenosis, history of solid organ transplant or dialysis, or history of 
cancer within the previous 5 years. Blood samples were collected from these patients at 
a single morning research study visit 61 ± 33 days from their index cardiac 
catheterization after fasting overnight and withholding morning medications. All patients 
were clinically stable and chest pain free at research visit, and were classified as stable 
CAD patients. 
Quantification of plasma eicosanoid metabolite  
All plasma levels of P450-derived eicosanoid metabolite concentrations were 
measured by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in 
106 consecutive CAD patients enrolled from 2007-2010 in a previous study, as 
described6. The specific biomarkers evaluated were sum EETs (the bioactive mediator 
in the CYP epoxygenase/EET pathway), 14,15-EET:DHET ratio (biomarker for sEH 
function), and 20-HETE (biomarker of 𝜔-hydroxylase pathway function).  
Quantification of urine TxA2 stable metabolite  
Concentrations of urinary stable metabolites of TxA2 and PGI2, 11-dehydro-
thromboxane B2 (TxA2-M) and 2,3-dinor-6-keto-prostaglandin F1 alpha (PGI2-M), were 
measured using ELISA kit (Cayman Chemical, Ann Arbor, MI, USA) according to 
manufacturer’s instructions in 123 of these patients in the same study population. The 
urine sample was a spot urine sample collected during the study visit. Urinary creatinine 
was quantified in the urine samples by McLendon Laboratories. The concentration 
quantified by the ELISA assay was normalized to urinary creatinine to account for inter-
individual differences in urine dilution, and the concentrations were expressed as pg/mg 
Cr. 
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Definition of major adverse cardiovascular events (MACE) 
 The primary endpoint, major adverse cardiovascular events (MACE) is defined 
as a composite of death due to any cause, hospitalization for non-fatal ACS events 
(unstable angina, non-ST segment elevation myocardial infarction [NSTEMI], STEMI), 
and hospitalization for non-fatal ischemic stroke or TIA. Secondary endpoints are each 
individual components of the composite, and an expanded MACE-revasc definition, 
which includes hospitalization for a coronary revascularization procedure (PCI or 
CAGB) in addition to MACE. Time-to-event from index research visit to first occurrence 
of MACE or last follow-up were also measured in each patient.  
The incidence of MACE were collected from electronic medical record at UNC 
health care system. If the patients did not come back to UNC for routine follow-up or 
emergent care, they were considered lost to follow-up and are excluded from analysis. 
By the end of this study, this patient population should have had 4-8 years of follow-up 
time. 
Statistical analysis 
Data are presented as mean ± standard deviation, median (interquartile range), 
or count (%) unless otherwise indicated. All analyses were performed using JMP Pro 
12.0.1 (SAS Institute, Cary, NC).  
Study population characteristics were described using descriptive statistics, and 
were compared across those with or without a MACE event using one-way ANOVA for 
continuous data and chi-squared test or Fisher’s exact test for categorical data as 
appropriate. Any variables that were not normally distributed were log-transformed. An 
association with p<0.05 is considered to be statistically significant. All analyses 
conducted with MACE were also repeated with the exploratory outcome MACE-revasc. 
The primary analysis was comparing log-transformed baseline plasma CYP 
eicosanoid metabolite levels (sum EETs, sum EETs + DHETs, 14,15-EET/DHET ratio, 
20-HETE) across patients with or without a future MACE event using one-way ANOVA, 
and using chi-square to compare frequency of future MACE when baseline plasma 
eicosanoid levels were grouped into tertiles.  
These analyses were also conducted with log-transformed baseline urine 
metabolite (TxA2-M and PGI2-M) levels and future MACE. In addition, three patients 
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were not taking aspirin at baseline, which were expected to have highest urine TxA2-M 
level. To ensure these 3 patients were not driving the association between TxA2-M and 
MACE, analyses were repeated in the population taking aspirin at baseline (n=109).  
Proportional hazard regression was used to evaluate the relationship between 
time to occurrence of first MACE (or MACE-revasc) and clinical factors, eicosanoid 
tertiles, and urine metabolite tertiles. Kaplan-Meier curves were generated using 
GraphPad Prism 6.0.  
To adjust for potential confounders of any observed associations, multivariable 
adjusted analyses were conducted to account for any demographic and clinical factors 
that were independently associated with MACE.  
 
Results 
Study population 
In the original study, 139 patients with stable CAD were enrolled, and 127 of 
them had follow-up visits after the initial research visit at UNC Health Care system, thus 
were included in the analysis. 96 of these patients had plasma eicosanoids quantified, 
and this population was used in all analysis with EETs eicosanoid metabolites. Urine 
TxA2-M and PGI2-M levels were quantified in 112 patients with available follow-up data 
(Figure 1).  
Baseline characteristics are similar in the overall population (n=127), population 
with EETs eicosanoid metabolites data (n=96), and population with urine prostaglandin 
metabolites data (n=112) (Table 1). In overall population, mean age is 59 years old, with 
28.3% female and 16.5% African Americans. 22% of patients had diabetes, 38.6% had 
prior MI. On screening catheterization visit, 33.1% of patients had ACS, 65.4% had 
multivessel disease, and 61.4% had a coronary artery stent placed. At baseline, 97.6% 
of patients were taking aspirin (3 patients not taking), and most patients were on 
guideline directed medical therapy for CAD. 
 
MACE and MACE-revasc event rates 
 Event rates of first MACE and MACE-revasc, as well as rates of each individual 
component, and time-to-first-event were summarized in Table 2. In the overall 
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population (n=127), MACE occurred in 28.3% of patients, and MACE-revasc occurred in 
36.2% of patients. The most likely first MACE event was ACS (20.5%), and unstable 
angina was the most likely ACS event. Median follow-up time in this population was 
5.64 years. Median time to first MACE or last follow-up was 4.75 years. In the patient 
populations where EETs eicosanoid data (n=96) and urine prostaglandin metabolite 
data (n=112) were available, event rates and time-to-event were similar to those in the 
overall population (Table 2). 
Associations between clinical factors and outcomes (MACE and MACE-revasc) 
were summarized in Table 3. Multivessel disease was an independent predictor of both 
MACE and MACE-revasc. In addition, diabetes, aspirin use, HDL and triglyceride levels 
were also independently associated with MACE-revasc, but results from proportional 
hazard analysis were not statistically significant for these clinical factors. 
Plasma eicosanoid metabolites and outcomes 
 In the population where plasma eicosanoid data were available (n=96), none of 
the CYP eicosanoid metabolite biomarkers analyses showed statistically significant 
association with either MACE or MACE-revasc (Table 4). As mentioned above, EETs 
are the bioactive metabolite of the pathway that had shown vasodilatory and 
cardioprotective effects in previous preclinical studies. Sum EETs + DHETs is a 
biomarker for the CYP enzyme functions of this pathway, while 14,15-EET/DHET ratio 
is a biomarker for sEH function. 20-HETE is a vasoconstrictor and has pro-inflammatory 
effect. It was shown to be associated with vascular dysfunction in previous study6.  
 In addition, no statistically significant associations were observed with either 
MACE or MACE-revasc when patients were grouped in tertiles based on baseline 
eicosanoid biomarker levels. Proportional hazard analysis did not yield any statistically 
significant results between baseline tertiles and either outcomes as well (Table 5 and 
Figure 2).  
Urine metabolites (TxA2 and PGI2) and outcomes 
Urine metabolite analysis was conducted in the population where these data 
were available (n=112). Urinary TxA2 metabolite levels at baseline appeared to be 
higher in those experiencing a future MACE (median [IQR] 792 [438] versus 579 [469]) 
or MACE-revasc event (median [IQR] 782 [586] versus 576 [425]), compared those 
Nan Wang 
Honor’s project paper 
Advisor: Craig Lee 
 8 
without a future event; however, these differences were not statistically significant (p 
equal 0.098 and 0.064, respectively) (Table 6). When baseline TxA2-M levels were 
grouped into tertiles, a significantly higher rate of MACE was observed across the 
lowest (18%), middle (33%) and highest (48%) TxA2-M tertiles (p=0.039). Compared to 
the lowest TxA2-M tertile, the highest tertile was associated with a significantly higher 
risk of MACE (hazard ratio 2.65, 95%CI 1.09-7.39, p =0.031); the middle tertile, 
however, did not exhibit a significantly higher risk of MACE (hazard ratio 1.61, 95%CI 
0.61-4.68, p=0.338) (Table 7A, Figure 3). The relationship between TxA2-M tertiles and 
MACE-revasc exhibits a similar trend, where MACE-revasc was observed more 
frequently with higher TxA2-M tertiles, and higher baseline TxA2-M tertile was 
associated with a higher risk for future MACE-revasc, although these results were not 
statistically significant (Table 7B, Figure 3).  
Since aspirin can lower TxA2 level, and is known to have cardioprotective effect, 
the use and dose of aspirin can potentially be confounding factors between the 
observed association of TxA2-M tertile and MACE. As expected, the patients who were 
not taking aspirin at baseline (n=3) had the highest TxA2 level (median[IQR] 2382.76 
[1614.63]), as compared to 37 patients on aspirin 81 mg (median[IQR] 838.98 [137.6]) 
and 72 patients on aspirin 325 mg (TxA2 median[IQR] 635.51 [539.7]). Median[IQR] of 
TxA2-M in healthy volunteers was 1990 pg/mgCr [1050]. Two of the three patients not 
taking aspirin had a MACE event, and all three had a MACE-revasc event. To confirm 
that the observed association between TxA2-M tertile and MACE was not solely driven 
by the use of aspirin, the above analyses were repeated with the three non-aspirin 
users excluded (n=109). The general trends persisted, however, the p value from chi-
square and logistic regression analyses were above 0.05 (p=0.0662 and 0.0619 
respectively). The association seen between highest TxA2-M tertile and MACE 
continued to be statistically significant in proportional hazard analysis (HR [95%CI] 2.51 
[1.01-7.10], p=0.048). 
Furthermore, clinical factors were compared across TxA2-M tertiles (Table 8). 
Diabetes and multivessel disease were found to be strongest independent predictors of 
MACE and were significantly different across TxA2-M tertiles (Table 8). In addition, other 
factors that could potentially be independently associated to MACE included aspirin 
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dose, age, sex, and race. Therefore, these 6 covariates (diabetes, multivessel disease, 
aspirin dose, age>65, sex, race) were adjusted in a multivariable model to confirm the 
association between TxA2-M tertiles and MACE, in the whole TxA2-M population 
(n=112) and population taking aspirin (n=109) (Table 9). The association between TxA2-
M and MACE persisted after adjusting for these covariates (Table 9).  
 
Discussions 
Inflammation has been well recognized as a key player in the pathogenesis of 
CAD2. Metabolites of arachidonic acid metabolic pathways, catalyzed by CYP enzymes, 
exhibit potent pro-inflammatory (EETs) or anti-inflammatory (20-HETE) effects3,4. 
Metabolites of the prostaglandin metabolite pathway, TxA2 and PGI2, have also been 
shown to have pro-inflammatory and anti-inflammatory effects, respectively, in addition 
to their roles in platelet regulation7,9. This study investigated the relationship between 
these arachidonic acid derived metabolites with major cardiovascular outcomes in order 
to translate our understanding of these pathways into clinically relevant applications. 
The current study did not find an association between CYP-derived EET or 20-HETE 
levels with MACE. On the other hand, elevated TxA2-M levels appeared to be 
associated with worse cardiovascular prognosis in patients with stable CAD, and this 
association was independent of aspirin use and dose at baseline. This suggests that 
extraplatelet sources of TxA2 may be an important driver of CAD progression and poor 
cardiovascular outcomes. 
 EETs are metabolites produced from arachidonic acids by CYP2J and CYP2C 
through epoxidation, and are subsequently rapidly hydrolyzed to less bioactive DHETs 
by sEH. As mentioned above, EETs have demonstrated potent vasodilatory, anti-
inflammatory and cardioprotective effects in a variety of preclinical models5. In parallel, 
20-HETE, generated by CYP4F and CYP4A 𝜔-hydroxylases, promote vasoconstriction, 
inflammation and myocardial injury in preclinical models4. A previous clinical study 
found that patients with obstructive CAD were predisposed to have low EETs levels 
secondary to suppressed EET biosynthesis11. Furthermore, higher plasma 20-HETE 
levels and enhanced sEH metabolic function were shown to be associated with vascular 
dysfunction in a population with stable CAD6, and vascular function was a well-
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established biomarker of prognosis in patients with established CAD.  However, this 
current study did not observe an association between function of CYP-derived 
metabolic pathways and MACE in patients with stable CAD. Importantly, based on 
preclinical evidence, novel pharmacologic agents to increase EET levels (sEH 
inhibitors) or to decrease 20-HETE levels (CYP 𝜔-hydroxylase inhibitors) are currently 
in development, and are hypothesized to be a promising therapeutic strategy for the 
secondary prevention of MACE in patients with established CAD in addition to standard 
therapy. Based on our current study, the association between metabolite biomarkers of 
these pathways and prognosis of CAD cannot be established. Future studies in a larger 
population are needed to validate the lack of a significant relationship between CYP-
derived eicosanoid levels and clinical outcomes in patients with stable CAD, as well as 
help to identify the subset of patients who are most likely to respond and benefit from 
these new therapies. 
TxA2 is a potent pro-thrombotic and pro-inflammatory mediator that regulates 
vascular reactivity, platelet activation, and cardiac function; while anti-thrombotic and 
anti-inflammatory PGI2 poses opposite effects on these processes9. Arachidonic acid is 
converted to intermediate mediator prostaglandin H2 by cyclooxygenases (COX-1 and 
COX-2) and further metabolized to a variety of bioactive molecule, including TxA2 and 
PGI2, by tissue-specific isomerases7. Low-dose aspirin used for prevention of MACE 
specifically targets COX-1 in platelets, thus blocking biosynthesis of TxA2 in platelets 
without significantly suppressing PGI2 biosynthesis in endothelial cells. However, about 
30% of TxA2 is produced from extraplatelet sources, including major inflammatory cells 
monocytes and macrophages in atherosclerotic lesions8. TxA2 is rapidly converted to 
more chemically stable and relatively biologically inactive metabolite TxB2, then further 
metabolized to stable urinary metabolite 11-dehydro-thromboxane B2 (TxA2-M). TxA2-
M serves as a reliable measure of total in vivo TxA2 including extraplatelet sources8. In 
this current study, higher baseline TxA2-M levels in urine was observed to be 
associated with increased risk of future MACE, and this result was independent of use 
and dose of aspirin at baseline; in contrast, no association was observed with PGI2-M 
levels. These data suggest that TxA2 from extraplatelet sources may be an important 
driver of CAD progression and poor cardiovascular outcomes.  
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Our observation of elevated TxA2-M levels being associated with poor 
cardiovascular outcomes in patients with stable CAD is consistent with previous 
literature reports (Table 10).  In patients with stable established CAD or multiple risk 
factors, Eikelboom et al. reported 1.66-1.8 fold increased risk of MACE (composite of 
MI, stroke, and cardiovascular death) in patients with highest quartile of TxA2-M 
compared to those in the lowest quartiles13,14. In addition, in patients with acute MI 
presented for primary PCI, Szczeklik et al. also found an 3.66 fold increased risk of 
MACE (composite of MI, stroke/TIA, cardiogenic shock pulmonary edema, nonfatal 
cardiac arrest, need for rescue PCI/CABG, and cardiovascular death) in patients with 
highest TxA2-M quartile compared to those with lowest quartiles15. Similarly, we 
observed a 2.65 fold (proportional hazard regression) or 3.94 (logistic regression) 
increased risk of MACE in patients with highest TxA2-M tertile compared to those with 
lowest tertile (Table 9), although definition of MACE in all these studies are slightly 
different. Importantly, compared to Heart Outcomes Prevention Evaluation (HOPE) 
Study and Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, 
Management and Avoidance (CHARISMA) Study, which were used as data sources by 
Eikelboom et al., our patient population exhibited a higher percentage of patients on 
guideline-directed medical therapy for CAD, yet elevated TxA2-M was still observed to 
be associated with poor cardiovascular outcome, suggesting additional interventions 
may be needed in this subset of patients.  
Importantly, the observed increased cardiovascular risk with elevated TxA2-M is 
independent of aspirin treatment or dose at baseline. Aspirin irreversibly inhibits platelet 
COX-1, and there are individuals whose COX-1, or any gene involved in the pathway 
that converts arachidonic acid to TxA2 and TxB2, has a single nucleotide 
polymorphisms (SNPs) that makes them less responsive to aspirin’s inhibition of platelet 
function in laboratory. However, SNPs associated with impaired laboratory response to 
aspirin were found not to be significantly associated with clinical outcomes16, although 
recent work had suggested that RNA profiles of platelet-specific genes could be used as 
novel biomarkers in identifying the subset of patients who might not respond to aspirin 
adequately and who were at increased risk for death and MI17,18.  Nonetheless, genetic 
variation alone may not fully explain the worsened cardiovascular prognosis with 
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baseline TxA2-M elevation observed in this study. Alternatively, TxA2 production from 
extraplatelet sources is not inhibited by low-dose aspirin. Inflammatory (monocytes and 
macrophages) and endothelial cells produce TxA2 via COX-2 pathway, and inhibition of 
these COX-2 pathways requires much higher doses of aspirin than daily low dose19. 
Arachidonic acid is metabolized in these alternative COX-2 pathways to prostaglandin 
H2, which can be shunted to platelets and further converted to TxA2 bypassing platelets 
COX-1, or can directly be converted to TxA2 in inflammatory and endothelial cells. This 
residue TxA2 not inhibited by aspirin, can activate platelets, and may be important in the 
pathogenesis of ACS. In fact, TxA2 was shown to be elevated during acute MI, and 
correlated with inflammatory markers during the acute phase15. TxA2-M levels decrease 
substantially when patients are out of the acute phase, but this cannot solely be 
explained by the long-term use of aspirin after MI15. The current study, together with 
previous studies, demonstrated that chronically elevated TxA2-M levels, despite aspirin 
treatment, was associated with higher risk of future MACE13,14,20.  
Novel agents targeting thromboxane pathway have been in clinical 
development21–23, namely thromboxane synthase inhibitors (TXSI), thromboxane 
receptor antagonists (TXRA), or dual action agents that combines the two. TXSIs aim to 
reduce biosynthesis of TxA2, mainly in platelets, by preventing conversion of PGH2 to 
effector TxA2. On the other hand, TXRAs block downstream effects of thromboxane 
receptors (TP), activated not only by TXA2, but also other ligands such as eicosanoids, 
endoperoxides, and isoprostanes. Expression of TPs is not limited to platelets. They are 
also expressed in inflammatory cells like macrophages and monocytes, as well as 
vascular endothelial cells and in atherosclerotic plaques21,22. Theoretically, compared to 
aspirin, TXSIs should be more selective, and TXRAs should exert additional benefit in 
inhibiting effects from not only platelet TxA2, but also extraplatelet TxA2 as well as 
endoperoxides and isoprostanes. Picotamide (dual TXSI/TXRA), ridogrel (dual 
TXSI/TXRA), and terutroban (TXRA) have all been studied clinically in patients with risk 
factors for thrombotic events21,22. However, results did not confirm substantial benefit 
over aspirin22,23, making it less desirable for industry to continue their development to 
compete with inexpensive aspirin. Our current study may provide some insights to 
rekindle this discussion by applying the principles of precision medicine. Due to the 
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observed relationship between elevated TxA2-M and prognosis of CAD, TxA2-M can 
potentially be used as a biomarker to guide therapy. That is rather than trying to replace 
aspirin with the novel TXSI/TXRA agents in the general population, these agents may 
be used in addition to aspirin in the subset of CAD patients who have persistently 
elevated TxA2-M level despite being on low-dose aspirin to further block the action of 
the thromboxane pathway. This biomarker-guided treatment approach may help to 
identify the patient population who can benefit the most from these novel agents. 
Further studies may be warranted to test the clinical effects of TXSI/TXRA as an adjunct 
to aspirin in this more selective patient population.  
Limitations of this study include its retrospective design and limited sample size. 
The observational design of this study precludes us from establishing causality between 
increased risk of MACE and elevated TxA2-M level. Furthermore, evaluation of multiple 
metabolites included multiple statistical comparisons, increasing the risk of false-
positive findings. Lastly, urinary TxA2 metabolites were measured in 112 of the 127 
evaluable patients enrolled in the study, which can potentially introduce selection bias. 
However, the baseline characteristics of patients in the cohort with urinary metabolite 
data are very similar to those of the overall population (Table 1), suggesting selection 
bias is unlikely. Nonetheless, the observed relationship requires validation in an 
independent population.  
Although preclinical studies showed promising results suggesting 
cardioprotective effects by raising EETs and suppressing 20-HETE levels, our study 
failed to establish a direct relationship between metabolic function of this pathway to 
prognosis of cardiovascular disease in patients with stable CAD. Future studies in a 
larger population are needed to revisit this issue, bridging our understanding of this 
pathway to clinical application and providing insights to novel therapy development 
targeting sEH and hydroxylases. On the other hand, our study showed that elevated 
TxA2-M level appeared to be associated with poor cardiovascular outcome, despite 
long-term aspirin treatment, consistent with previous literature. Moreover, compared to 
previous studies, even with more optimized guideline directed medical therapy at 
baseline, this relationship still persists, suggesting the subset of patients with elevated 
TxA2-M may benefit from additional therapy that specifically lowers residue TxA2-M 
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levels in addition to guideline directed medical therapy. This demonstrates the potential 
value of using TxA2-M as a biomarker to predict cardiovascular outcomes, as well as to 
guide therapy selection. Future studies are needed to validate these results in a larger 
population, to investigate the causes of increased extraplatelet TxA2 biosynthesis in 
certain individuals, and to develop therapeutic interventions that mitigate the risk of 
elevated TxA2 levels in CAD patients on aspirin therapy.  
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Tables 
Table 1. Baseline characteristics of stable CAD patients with UNC follow-up. Data are 
presented as count (%), median (interquartile range), and mean ± SD unless otherwise 
indicated. EETs= epoxyeicosatrienoic acids, MI = myocardial infarction, BMI=body mass 
index, PCI=percutaneous coronary intervention, CABG=coronary artery bypass graft, 
ACE-I=angiotensin-converting enzyme inhibitor, ARB=angiotensin receptor blocker, 
NSTEMI=non-ST segment elevation myocardial infarction, STEMI=ST segment 
elevation myocardial infarction, LDL=low-density lipoprotein, HDL=high-density 
lipoprotein. 
 All patient (n=127) 
EETs eicosanoid 
group (n=96) 
Prostaglandin 
metabolite group 
(n=112) 
Age in years  59.46 ± 9.93 58.05 ± 9.80 59.71 ± 9.94 
Age >65  35 (27.6%) 22 (22.9%) 30 (26.8%) 
Female  36 (28.3%) 29 (30.2%) 31 (27.7%) 
African American  21 (16.5%) 16 (16.7%) 19 (17.0%) 
Past Medical History    
Current smoker  27 (21.1%) 19 (19.8%) 25 (22.3%) 
Diabetes  28 (22.0%) 21 (21.9%) 26 (23.2%) 
Hypertension  106 (83.5%) 79 (82.3%) 95 (84.8%) 
BMI in kg/m2  29.81 ± 5.4 30.32 ± 5.53 29.76 ± 5.48 
Obesity (BMI >=30)  60 (47.2%) 52 (54.2%) 51 (45.5%) 
Prior MI 49 (38.6%) 36 (37.5%) 45 (40.2%) 
Prior stroke  8 (6.3%) 6 (6.3%) 5 (4.5%) 
Prior PCI  55 (43.3%) 43 (44.8%) 52 (46.4%) 
Medication use at baseline    
Aspirin  124 (97.6%) 93 (96.9%) 109 (97.3%) 
Aspirin dose at baseline     
81 mg 46 (36.22%) 35 (36.46%) 37 (33.0%) 
325 mg 78 (61.42%) 58 (60.42%) 72 (64.3%) 
Statins  118 (92.9%) 89 (92.7%) 104 (92.9%) 
Beta Blockers  107 (84.3%) 82 (85.4%) 94 (83.9%) 
ACE-I or ARB  81 (63.8%) 61 (63.5%) 71 (63.4%) 
Clopidogrel  101 (79.5%) 75 (78.1%) 89 (79.5%) 
Indication of catheterization lab 
visit at screening    
Stable angina  85 (66.9%) 69 (71.8%) 75 (67.0%) 
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Unstable angina  21 (16.5%) 12 (12.5%) 18 (16.1%) 
NSTEMI  18 (14.2%) 14 (14.6%) 16 (14.3%) 
STEMI  3 (2.4%) 1 (1%) 3 (2.7%) 
Catheterization lab 
findings and 
interventions 
   
Multivessel disease  83 (65.4%) 65 (67.7%) 72 (64.3%) 
Stent placement  78 (61.4%) 53 (55.2%) 68 (60.7%) 
Post CABG  11 (8.7%) 10 (10.4%) 9 (8.0%) 
Post revascularization 91 (71.7%) 65 (67.7%) 79 (70.5%) 
Labs at baseline    
Systolic blood pressure (mmHg)  133 (21) 133 (20) 133 (21) 
Diastolic blood pressure (mmHg)  78 (13) 79 (13) 78 (13) 
Total cholesterol (mg/dL)  155 (53) 156 (49) 155 (53) 
LDL (mg/dL)  85 (41) 84 (35) 84 (42) 
HDL (mg/dL) 47 (17) 47 (17) 47 (17) 
Triglyceride (mg/dL)  97 (80) 98 (74) 96 (84) 
Blood Glucose (mg/dL) 96 (14) 96 (15) 96 (15) 
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Table 2. Incidence and time-to-event rate of first MACE and MACE-revasc event in 
patients with stable CAD patients and UNC follow-up. Data are presented as count (%) 
and median (interquartile range) unless otherwise indicated. EETs= epoxyeicosatrienoic 
acids, MACE=major adverse cardiovascular event, ACS=acute coronary syndrome, 
TIA=transient ischemic attack, PCI=percutaneous coronary intervention, 
CABG=coronary artery bypass graft, NSTEMI=non-ST segment elevation myocardial 
infarction, STEMI=ST segment elevation myocardial infarction. 
 
All patient  
(n=127) 
EETs eicosanoid 
group (n=96) 
Prostaglandin 
metabolite group 
(n=112) 
MACE 36 (28.3%) 32 (33.3%) 33 (29.5%) 
Death (all cause) 6 (4.7%) 6 (6.3%) 5 (4.5%) 
ACS 26 (20.5%) 23 (24.0%) 24 (21.4%) 
Unstable Angina 17 (13.4%) 16 (16.7%) 16 (14.3%) 
NSTEMI 7 (5.5%) 5 (5.2%) 6 (5.4%) 
STEMI 2 (1.6%) 2 (2.1%) 2 (1.8%) 
Stroke/TIA 4 (3.2%) 3 (3.1%) 4 (3.6%) 
Stroke 2 (1.6%) 1 (1.0%) 2 (1.8%) 
TIA 2 (1.6%) 2 (2.1%) 2 (1.8%) 
MACE-revasc  46 (36.2%) 40 (41.7%) 42 (37.5%) 
Death (all cause) 6 (4.7%) 6 (6.3%) 5 (4.5%) 
ACS 22 (17.3%) 19 (19.8%) 21 (18.8%) 
Unstable Angina 13 (10.2%) 12 (12.5%) 13 (11.6%) 
NSTEMI 7 (5.5%) 5 (5.2%) 6 (5.4%) 
STEMI 2 (1.6%) 2 (2.1%) 2 (1.8%) 
Stroke/TIA 4 (3.2%) 3 (3.1%) 4 (3.6%) 
Stroke 2 (1.6%) 1 (1.0%) 2 (1.8%) 
TIA 2 (1.6%) 2 (2.1%) 2 (1.8%) 
Revascularization for stable CAD 14 (11.0%) 12 (12.5%) 12 (10.7%) 
PCI 14 (11.0%) 12 (12.5%) 12 (10.7%) 
CABG 0 (0%) 0 (0%) 0 (0%) 
Time to events (in years)     
Time to MACE or last follow-up  4.75 (2.56-6.37) 5.38 (1.63-6.68) 4.72 (2.53-6.22) 
Time to MACE-revasc or last follow-up  4.54 (1.69-6.06) 6.97 (1.27-6.54) 4.56 (1.73-5.95) 
Time to last follow-up  5.64 (4.15-6.85) 8.57 (5.08-7.24) 5.62 (4.15-6.71) 
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Table 3. Clinical factors across patients with or without MACE (panel A) and MACE-
revasc (panel B), as well proportional hazard analysis results for each outcome in 
n=127. P valued highlighted in bold indicates that the clinical factor is statistically 
significantly associated with outcomes. Data are presented as count (%), median 
(interquartile range), and mean ± SD unless otherwise indicated. MI = myocardial 
infarction, BMI=body mass index, PCI=percutaneous coronary intervention, 
CABG=coronary artery bypass graft, ACE-I=angiotensin-converting enzyme inhibitor, 
ARB=angiotensin receptor blocker, NSTEMI=non-ST segment elevation myocardial 
infarction, STEMI=ST segment elevation myocardial infarction, LDL=low-density 
lipoprotein, HDL=high-density lipoprotein, BG=blood glucose, HR=hazard ratio, 95% 
CI=95% confidence interval.  
A Chi-square/Fisher’s Exact, ANOVA Proportional Hazard 
 
MACE  
(n=36) 
no MACE 
(n=91) P HR 95% CI p 
Age in years 59.14 ± 1.66 59.58 ± 1.04 0.822    
Age >65 8 (22.2%) 27 (29.7%) 0.397 0.72 0.31-1.51 0.403 
Female 9 (25.0%) 27 (29.7%) 0.599 0.70 0.31-1.44 0.350 
African American 6 (16.7%) 15 (16.5%) 0.980 1.04 0.39-2.32 0.935 
Current smoker 9 (25.0%) 18 (19.8%) 0.517 1.40 0.62-2.86 0.400 
Diabetes 12 (33.3%) 16 (17.6%) 0.054 1.82 0.88-3.57 0.103 
Hypertension 29 (80.6%) 77 (84.6%) 0.579 0.90 0.42-2.24 0.806 
BMI in kg/m2 30.95 ± 0.90 29.36 ± 0.56 0.135    
Obesity (BMI ≥30) 20 (55.6%) 40 (44.0%) 0.238 1.48 0.77-2.91 0.238 
Prior MI 16 (44.4%) 33 (36.2%) 0.393 1.34 0.68-2.58 0.389 
Prior stroke 3 (8.3%) 5 (5.5%) 0.687 1.74 0.42-4.87 0.395 
Prior PCI 17 (47.2%) 38 (41.8%) 0.575 1.28 0.65-2.45 0.474 
Aspirin 34 (94.4%) 90 (98.9%) 0.193 0.37 0.11-2.30 0.238 
Aspirin dose*   0.276    
81 mg 10 (29.4%) 36 (40.0%)     
325 mg 24 (70.6%) 54 (60.0%)     
Statins 32 (88.9%) 86 (94.5%) 0.271 0.60 0.24-2.02 0.371 
Beta Blockers 31 (86.1%) 76 (83.5%) 0.718 1.40 0.60-4.11 0.467 
ACE-I or ARB 25 (69.4%) 56 (61.5%) 0.404 1.31 0.66-2.78 0.444 
Clopidogrel 29 (80.6%) 72 (79.1%) 0.857 1.12 0.52-2.79 0.780 
ACS 9 (25.0%) 34 (37.3%) 0.185 0.65 0.29-1.34 0.255 
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Multivessel disease 29 (80.6%) 54 (59.3%) 0.024 2.57 1.19-6.38 0.015 
Stent placement 18 (50.0%) 60 (65.9%) 0.096 0.62 0.32-1.20 0.151 
Post CABG 5 (13.9%) 6 (6.6%) 0.188 1.74 0.59-4.11 0.283 
Post 
revascularization 24 (66.7%) 67 (73.6%) 0.433 0.79 0.40-1.64 0.512 
Systolic blood 
pressure (mmHg) 135 (122-151) 133 (125-143) 0.794    
Diastolic blood 
pressure (mmHg) 79 (73-86) 78 (72-85) 0.724    
Total cholesterol 
(mg/dL) 167 (143-192) 154 (129-183) 0.407    
LDL (mg/dL) 88 (71-114) 83 (62-104) 0.340    
HDL (mg/dL) 45 (36-56) 48 (40-56) 0.271    
Triglyceride (mg/dL) 110 (81-153) 94 (70-159) 0.279    
BG (mg/dL) 96 (90-111) 96 (90-103) 0.998    
*Only in patients who were taking aspirin at baseline, n=124 
 
B Chi-square/Fisher’s Exact, ANOVA Proportional Hazard 
 
MACE-revasc 
(n=46) 
no MACE-
revasc (n=81) P HR 95% CI p 
Age in years 59.89 ± 1.47 59.21 ± 1.11 0.712    
Age >65 13 (28.3%) 22 (27.2%) 0.894 1.03 0.52-1.92 0.921 
Female 12 (26.1%) 24 (29.6%) 0.670 0.76 0.38-1.43 0.403 
African American 7 (15.2%) 14 (17.3%) 0.763 0.90 0.37-1.90 0.801 
Current smoker 10 (21.7%) 17 (21.0%) 0.921 1.10 0.52-2.14 0.788 
Diabetes 15 (32.6%) 13 (16.1%) 0.031 1.83 0.96-3.34 0.065 
Hypertension 39 (84.8%) 67 (82.7%) 0.763 1.19 0.56-2.90 0.673 
BMI in kg/m2 30.99 ± 0.79 29.14 ± 0.59 0.064    
Obesity (BMI ≥30) 25 (54.4%) 35 (43.2%) 0.227 1.46 0.82-2.63 0.201 
Prior MI 19 (41.3%) 30 (37.0%) 0.635 1.15 0.63-2.06 0.643 
Prior stroke 4 (8.7%) 4 (4.9%) 0.459 1.98 0.59-4.91 0.237 
Prior PCI 22 (47.8%) 33 (40.7%) 0.439 1.32 0.74-2.37 0.344 
Aspirin 43 (93.5%) 81 (100%) 0.046 0.24 0.09-1.02 0.052 
Aspirin dose*   0.249    
81 mg 13 (30.2%) 33 (40.7%)     
325 mg 30 (69.8%) 48 (59.3%)     
Statins 41 (89.1%) 77 (95.1%) 0.211 0.60 0.26-1.75 0.317 
Beta Blockers 40 (87.0%) 67 (82.7%) 0.528 1.55 0.71-4.08 0.292 
ACE-I or ARB 34 (73.9%) 47 (58.0%) 0.073 1.65 0.88-3.32 0.124 
Clopidogrel 37 (80.4%) 64 (79.0%) 0.849 1.16 0.59-2.56 0.686 
Nan Wang 
Honor’s project paper 
Advisor: Craig Lee 
 22 
ACS 15 (32.6%) 28 (34.6%) 0.823 0.98 0.51-1.78 0.946 
Multivessel disease 37 (80.4%) 46 (56.8%) 0.007 2.67 1.34-5.90 0.004 
Stent placement 24 (52.2%) 54 (66.7%) 0.107 0.68 0.38-1.22 0.191 
Post CABG 6 (13.0%) 5 (6.17%) 0.186 1.62 0.62-3.54 0.300 
Post 
revascularization 32 (69.6%) 59 (72.8%) 0.694 0.93 0.50-1.79 0.808 
Systolic blood 
pressure (mmHg) 138 (123-150) 133 (125-143) 0.563    
Diastolic blood 
pressure (mmHg) 80 (74-87) 77 (72-85) 0.346    
Total cholesterol 
(mg/dL) 160 (143-185) 152 (128-183) 0.38    
LDL (mg/dL) 87 (69-109) 83 (63-104) 0.439    
HDL (mg/dL) 43 (36-55) 48 (41-56) 0.031    
Triglyceride (mg/dL) 123 (87-169) 91 (69-126) 0.006    
BG (mg/dL) 97 (90-111) 96 (89-102) 0.148    
*Only in patients who were taking aspirin at baseline, n=124 
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Table 4. Results from one-way ANOVA analysis of log-transformed CYP eicosanoid 
metabolite biomarker levels and MACE and MACE-revasc (n=96). Biomarker levels are 
expressed as median (interquartile range). EETs=epoxyeicosatrienoic acids, 
DHETS=dihydroxyeicosatrienoic acids, 20-HETE=20-hydroxyeicosatetreanoic acid. 
Eicosanoid 
metabolite 
MACE  
(n=32) 
no MACE 
(n=64) P 
MACE-
revasc 
(n=40) 
no MACE-
revasc 
(n=56) 
P 
Sum plasma 
EETs (ng/mL) 
0.29  
(0.23-0.42) 
0.31  
(0.21-0.40) 0.874 
0.30  
(0.23-0.43) 
0.30  
(0.21-0.39) 
0.719 
 
Sum EETs + 
DHETs (ng/mL) 
1.78  
(1.38-2.09) 
1.58  
(1.39-2.31) 0.966 
1.67  
(1.36-2.09) 
1.59  
(1.40-2.34) 
0.952 
 
14, 15-
EET/14,15-DHET 
ratio 
0.37  
(0.17-0.74) 
0.38 
(0.17-0.71) 0.918 
0.42  
(0.18-0.81) 
0.31 
 (0.16-0.63) 0.631 
20-HETE (ng/mL) 1.55  (1.03-2.30) 
1.58  
(1.19-2.23) 0.381 
1.55  
(1.14-2.30) 
1.58 
 (1.18-2.23) 0.466 
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Table 5. Chi-square and proportional hazard analysis with plasma eicosanoid 
metabolite tertiles and MACE (panel A) or MACE-revasc (panel B) (n=96). HR=hazard 
ratio, 95% CI=95% confidence interval. EETs=epoxyeicosatrienoic acids, 
DHETS=dihydroxyeicosatrienoic acids, 20-HETE=20-hydroxyeicosatetreanoic acid. 
A Chi-square Proportional hazard 
Tertiles MACE  (n=32) 
no MACE 
(n=64) P HR 95% CI P 
Sum EETs (ng/mL)   0.829   0.791 
0 12 (37.5%) 20 (31.3%)  Reference   
1 10 (31.3%) 22 (34.4%)  0.77 0.32-1.77 0.531 
2 10 (31.3%) 22 (34.4%)  0.79 0.33-1.83 0.582 
Sum EETs + DHETs 
(ng/mL)    0.720   0.772 
0 9 (28.1%) 23 (35.9%)  Reference   
1 12 (37.5%) 20 (31.3%)  1.36 0.58-3.35 0.480 
2 11 (34.4%) 21 (32.8%)  1.24 0.51-3.10 0.631 
14, 15-EET/14,15-
DHET ratio    0.954   0.956 
0 10 (31.3%) 22 (34.4%)  Reference   
1 11 (34.4%) 21 (32.8%)  1.14 0.48-2.74 0.769 
2 11 (34.4%) 21 (32.8%)  1.09 0.46-2.64 0.839 
20-HETE (ng/mL)    0.954   0.928 
0 11 (34.4%) 21 (32.8%)  Reference   
1 10 (31.3%) 22 (34.4%)  0.85 0.35-2.01 0.700 
2 11 (34.4%) 21 (32.8%)  0.91 0.39-2.13 0.825 
 
B Chi-square Proportional hazard 
Tertiles MACE-revasc (N=40) 
no MACE-
revasc 
(n=56) 
P HR 95% CI P 
Sum EETs (ng/mL)   0.741   0.722 
0 13 (32.5%) 19 (33.9%)  Reference   
1 12 (30.0%) 20 (35.7%)  0.89 0.30-1.96 0.765 
2 15 (37.5%) 17 (30.4%)  1.21 0.57-2.58 0.618 
Sum EETs + DHETs 
(ng/mL)   0.96   0.971 
0 13 (32.5%) 19 (33.9%)  Reference   
1 14 (35.0%) 18 (32.1%)  1.07 0.50-2.30 0.863 
2 13 (32.5%) 19 (33.9%)  0.98 0.45-2.13 0.945 
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14, 15-EET/14,15-
DHET ratio   0.573   0.573 
0 11 (27.5%) 21 (37.5%)  Reference   
1 14 (35.0%) 18 (32.1%)  1.39 0.63-3.14 0.410 
2 15 (37.5%) 17 (30.4%)  1.48 0.68-3.30 0.323 
20-HETE (ng/mL)   0.573   0.594 
0 15 (37.5%) 17 (30.4%)  Reference   
1 11 (27.5%) 21 (37.5%)  0.67 0.30-1.45 0.309 
2 14 (35.0%) 18 (32.1%)  0.85 0.41-1.77 0.662 
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Table 6. Results from one-way ANOVA analysis of log-transformed urine prostaglandin 
metabolite levels and MACE and MACE-revasc (n=112). Biomarker levels are 
expressed as median [interquartile range]. TxA2-M (11-dehydro-thromboxane B2) is the 
stable urine metabolite of thromboxane (TxA2). PGI2-M (2,3-dinor-6-keto-prostaglandin 
F1 alpha) is the stable urine metabolite of prostacyclin (PGI2).  
Urine 
metabolites MACE (n=33) no MACE (n=79) P 
MACE-revasc 
(n=42) 
no MACE-
revasc (n=70) P 
TxA2-M 
(pg/mg Cr) 
791.84 
(606.24-1044.43) 
579.19  
(408.59-877.69) 0.098 
782.34  
(490.79-1077.21) 
575.64  
(405.41-830.35) 0.064 
PGI2-M  
(pg/mg Cr) 
10060.89  
(5734.21-16152.48) 
10076.40  
(6000.88-16399.99) 0.401 
8044.70  
(5167.38-15771.61) 
10842.65  
(6103-16789.98) 0.324 
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Table 7. Chi-square and proportional hazard analysis with urine thromboxane 
metabolite tertiles and MACE (panel A) or MACE-revasc (panel B) (n=112). TxA2-M 
(11-dehydro-thromboxane B2) is the stable urine metabolite of thromboxane (TxA2). 
HR=hazard ratio, 95% CI=95% confidence interval. P-values in bold indicates statistical 
significance. 
A Chi-square Proportional hazard 
Tertiles MACE (n=33) 
no MACE 
(n=79) P HR 95% CI P 
TxA2-M  
(pg/mg Cr)   0.039   0.092 
0 6 (18.2%) 31 (39.2%)  Reference   
1 11 (33.3%) 27 (34.2%)  1.61 0.61-4.68 0.338 
2 16 (48.5%) 21 (26.6%)  2.65 1.09-7.39 0.031 
 
B Chi-square Proportional hazard 
Tertiles MACE-revasc (n=42) 
no MACE-
revasc 
(n=70) 
P HR 95% CI P 
TxA2-M  
(pg/mg 
Cr)    0.085   0.215 
0 10 (23.8%) 27 (38.6%) 
 
Reference   
1 13 (31.0%) 25 (35.7%) 
 
1.07 0.47-2.51 0.871 
2 19 (45.2%) 18 (25.7%) 
 
1.80 0.86-4.04 0.123 
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Table 8. Clinical factors across TxA2-M tertiles (n=112). The associations between 
these factors and TxA2-M tertile were determined by chi-square/Fisher’s exact for 
nominal variable and one-way ANOVA for continuous variable. P values in bold 
indicates statistical significance. Data are presented as count (%), median (interquartile 
range), and mean ± SD unless otherwise indicated. MI = myocardial infarction, 
BMI=body mass index, PCI=percutaneous coronary intervention, CABG=coronary 
artery bypass graft, ACE-I=angiotensin-converting enzyme inhibitor, ARB=angiotensin 
receptor blocker, NSTEMI=non-ST segment elevation myocardial infarction, STEMI=ST 
segment elevation myocardial infarction, LDL=low-density lipoprotein, HDL=high-density 
lipoprotein, BG=blood glucose. 
 Tertile 1 (n=37) Tertile 2 (n=38) Tertile 3 (n=37) P 
Age in years  61.54 ± 10.74 60.21 ± 9.56 57.38 ± 9.30 0.185 
Age >65  12 (32.0%) 11 (28.9%) 7 (18.9%) 0.395 
Female  2 (5.4%) 13 (34.2%) 16 (43.2%) 0.0003 
African American  4 (10.8%) 5 (13.2%) 10 (27.0%) 0.158 
Current smoker  4 (10.8%) 8 (21.0%) 13 (35.1%) 0.047 
Diabetes  7 (18.9%) 6 (15.8%) 13 (35.1%) 0.105 
Hypertension  32 (86.5%) 30 (78.9%) 33 (89.0%) 0.509 
BMI in kg/m2  28.59 ± 4.14 29.82 ± 5.42 30.86 ± 6.54 0.207 
Obesity (BMI >=30)  12 (32.0%) 19 (50.0%) 20 (54.1%) 0.139 
Prior MI  15 (40.5%) 15 (39.5%) 15 (40.5%) 0.994 
Prior stroke  2 (5.4%) 2 (5.3%) 1 (2.7%) 1.000 
Prior PCI  19 (51.3%) 17 (44.7%) 16 (43.2%) 0.758 
Aspirin  37 (100%) 38 (100%) 34 (91.9%) 0.068 
Aspirin dose at baseline*     0.654 
81 mg 11 (29.7%) 15 (39.5%) 11 (32.4%)  
325 mg 26 (70.3%) 23 (60.5%) 23 (67.7%)  
Statins  37 (100%) 36 (94.7%) 31 (83.8%) 0.019 
Beta Blockers 34 (91.9%) 30 (78.9%) 30 (81.1%) 0.265 
ACE-I or ARB  24 (64.9%) 24 (63.2%) 23 (62.2%) 0.971 
Clopidogrel  32 (86.5%) 30 (78.9%) 27 (73.0%) 0.354 
ACS  17 (45.9%) 10 (26.3%) 11 (29.7%) 0.161 
Multivessel disease  25 (67.6%) 22 (57.9%) 25 (67.6%) 0.600 
Stent placement  24 (64.9%) 24 (63.2%) 20 (54.1%) 0.591 
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Post CABG  2 (5.4%) 4 (10.5%) 3 (8.1%) 0.907 
Post revascularization  27 (73.0%) 28 (73.4%) 24 (64.8%) 0.651 
Systolic blood pressure (mmHg)  130 (14) 134 (21) 135 (25) 0.610 
Diastolic blood pressure (mmHg)  77 (9) 76 (9) 83 (15) 0.040 
Total cholesterol (mg/dL)  135 (47) 153 (27) 183 (47) 0.0001 
LDL (mg/dL) 74 (40) 82 (26) 103 (50) 0.0001 
HDL (mg/dL)  44 (16) 48 (17) 48 (26) 0.175 
Triglyceride (mg/dL)  94 (89) 97 (70) 102 (91) 0.981 
BG (mg/dL)  97 (12) 95 (16) 98 (18) 0.142 
*Only in patients who were taking aspirin at baseline, n=109 
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Table 9. Unadjusted and adjusted logistic regression and proportional hazard analysis 
between urine TxA2-M tertiles and MACE, in whole population with TxA2 data (n=112) 
(top panel) and population with non-aspirin users excluded (n=109) (bottom panel). P 
values in bold indicate statistically significant results. The association between TxA2-M 
tertile and MACE persists after adjusting for potential confounders and excluding 
patients not taking aspirin. OR=odds ratio, HR=hazard ratio, 95% CI=95% confidence 
interval. 
n=112 Unadjusted Adjusted 
 Logistic regression Proportional hazard Logistic regression Proportional hazard 
Tertiles OR  
(95% CI) P 
HR 
(95%CI) P 
OR  
(95% CI) P 
HR 
(95%CI) P 
TXA2-M  
(pg/mg Cr) 
 0.036  0.092  0.014  0.059 
0 Reference  Reference  Reference  Reference  
1 
2.11 
(0.70-6.83) 0.185 
1.61 
(0.61-4.68) 0.338 
3.51 
(1.05-12.91) 0.041 
2.2  
(0.81-6.54) 0.122 
2 3.94 
(1.38-12.52) 0.010 
2.65 
(1.09-7.39) 0.031 
6.23  
(1.75-25.13) 0.004 
3.34  
(1.22-10.00) 0.019 
 
n=109 Unadjusted Adjusted 
 Logistic regression Proportional hazard Logistic regression Proportional hazard 
Tertiles OR  
(95% CI) P 
HR 
(95%CI) P 
OR  
(95% CI) P 
HR 
(95%CI) P 
TXA2-M  
(pg/mg Cr)  0.062  0.140  0.012  0.055 
0 Reference  Reference  Reference  Reference  
1 
2.11 
(0.70-6.83) 0.185 
1.61 
(0.61-4.68) 0.338 
3.67 
(1.09-13.82) 0.036 
2.28  
(0.84-6.81) 0.107 
2 3.62 
(1.24-11.69) 0.018 
2.51 
(1.01-7.10) 0.048 
6.56 
(1.81-27.20) 0.004 
3.4  
(1.24-10.22) 0.017 
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Table 10. Evidence regarding association between TxA2 and MACE. CAD=coronary 
artery disease, MACE=major adverse cardiovascular events, CCB=calcium channel 
blocker, HOPE Study=Heart Outcomes Prevention Evaluation Study, CHARISMA 
Study= Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, 
Management and Avoidance Study, NSAIDs=non-steroidal anti-inflammatory drugs, 
ACE-I=angiotensin-converting enzyme inhibitor, ARB=angiotensin receptor blocker, 
PAD=peripheral artery disease, ACS=acute coronary syndrome, SVG=saphenous vein 
graft, CABG=coronary artery bypass graft, LMWH=low molecular weight heparin, COX-
1=cyclooxygenase-1, MI=myocardial infarction, PCI=percutaneous coronary 
intervention, LTIMI Study=leukotrienes and Thromboxane in Myocardial Infarction Study, 
hs-CRP=high-sensitivity C-reactive protein, WBC=white blood cell, hs-TnT=high-
sensitivity troponin T, OR=odds ratio, HR=hazard ratio, 95% CI=95% confidence 
interval. 
Study Design Relationship between 
TxA2 and MACE 
Patient population Background therapy  
Eikelboom 
et al. 200213 
Case-control 
design 
Patients in the upper 
quartile of urinary 11-
dehydro thromboxane B2 
having a 1.8-times-higher 
risk of MACE (composite 
of MI, stroke, or 
cardiovascular death) than 
those in the lower quartile 
(OR 1.8; 95% CI 1.2-2.7; 
P=0.009) 
Canadian patients 
enrolled in HOPE Study 
(stable CAD, 1993-
1999), 488 cases 
treated with aspirin who 
had MACE during 5-yr 
follow-up and 488 
controls treated with 
aspirin but no MACE 
In case group: 100% 
aspirin, 49% beta-
blocker, 25% lipid-
lowering agent, 15% 
diuretics, 59% CCB, 
46.5% Ramipril, 50% 
vitamin E 
Eikelboom 
et al. 200814 
 
Externally 
validate results 
from the study 
mentioned 
above. 
Prespecified 
sub-study of the 
CHARISMA 
study 
Baseline urinary 11-
dehydro thromboxane B2 
concentrations in the 
highest quartile were 
associated with an 
increased risk of stroke, 
MI, or cardiovascular death 
compared with the lowest 
quartile (adjusted HR 1.66, 
95% CI 1.06-2.61, 
P=0.03).  
15603 patients with 
either clinically 
established CAD or 
multiple risk factors 
In all patients: 99.7% 
aspirin, 55% 
clopidogrel, 21.6% 
NSAIDs, 76.9% 
statin, 55.3% beta-
blocker, 47.6% 
diuretic, 36.8% CCB, 
18% ramipril, 46.3% 
other ACE-I, 12.4% 
other 
antihypertensives, 
34.3% oral 
antihyperlycemic 
agents, 17.3% insulin 
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Krasopoulos 
et al. 200824  
meta-analysis of 
20 studies 
(1997-2007), 
total of 2930 
patients 
All aspirin resistant 
patients, regardless of 
underlying clinical 
symptoms, were at a 
greater risk of death, ACS, 
failure in vascular 
intervention, or a new 
cerebrovascular event: 
39% of aspirin resistant 
patients compared with 
16% of aspirin sensitive 
patients had a 
cardiovascular event (OR 
3.85, 95% CI 3.08 to 4.80; 
P<0.001) 
Cardiovascular disease 
(CAD, PAD or 
cerebrovascular 
disease) patients  
N/A 
Gluckman 
et al.25, 
2011 
ASA 
responsiveness 
and platelet 
reactivity 
measured 2-4 
days after CABG 
surgery and 6 
months after 
when SVG 
patency was 
assessed 
Elevated Urine TxB2 
increases risk of early SVG 
thrombosis after CABG 
surgery.  
368 patients after first-
time CABG surgery 
with implantation of at 
least 1 SVG.  
100% aspirin, 4-6% 
oral anticoagulation, 
61-62% ACE-i/ARB, 
81-89% beta-blocker, 
86-91% lipid lowering 
agent 
Frelinger et 
al.20 2009 
Prospectively 
determine 
whether COX-1 
dependent and 
other platelet 
function assays 
correlate with 
clinical 
outcomes in 
aspirin-treated 
patients 
This study is to look at 
serum TxB2 not urine 
metabolite. Serum TxB2 
evaluates the capacity of 
maximally activated 
platelets to produce 
thromboxane via COX-1, 
which urinary 11-dehydro-
TxB2 reflects total amount 
that can be derived in part 
from non-platelet sources. 
Nonetheless, this study 
showed elevated serum 
TxB2 is associated with an 
increase risk for MACE in 
this population 
700 consecutive 
aspirin-treated patient 
presenting for 
diagnostic angiographic 
evaluation of CAD 
6% COX-2 inhibitors, 
10% NSAIDs, 32% 
clopidogrel, 11% 
heparin, 4% warfarin, 
8% LMWH, 23% 
CCB, 29% diuretic, 
7% insulin, 19% oral 
hypoglycemic, 19% 
antidepressants 
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Szczeklik et 
al. 15 2016 
part of the LTIMI 
study to 
evaluate the 
relationship 
between 11-
dehydro-TxB2 
and MACE in 
patients with 
acute MI. 
Urinary 11-
dehydro-TxB2 
measured on 
admission, 1 
month, 1 year 
Baseline 11-dehydro-TXB2 
was higher in patients with 
MACEs (n=60; 7.73, 7.07–
8.60) compared with those 
without MACEs (n=119; 
7.28, 6.68–7.79; P=0.002). 
Univariate analysis 
revealed 3.66 times (95% 
CI 1.47–9.13) higher 
MACE risk in patients 
within the highest 11-
dehydro-TXB2 quartile, 
com- pared with those in 
the lowest 
quartile.Baseline 11-
dehydro-TxB2 also 
correlated with CK, hs-
TnT, and inflammatory 
markers (WBC, hs-CRP)  
 
180 consecutive 
patients with acute MI 
type 1 referred for 
primary PCI.  
Aspirin and 
clopidogrel were 
administered to all 
patients at least 30 
minutes before the 
urine sample 
collection. In the 
studied group, 54 
(30%) patients 
received aspirin on a 
long-term basis 
before admission, 
and 11 (6.1%) 
additional patients 
were taking 
clopidogrel. By 
discharge from the 
hospital, all patients 
were taking aspirin, 
and 94.4% were 
taking clopidogrel 
(except 10 patients 
scheduled for CABG). 
Other therapies not 
reported 
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Figures 
 
Figure 1. Study population definitions. Only patients with UNC follow-up (n=127) were 
included in the analysis. The subpopulations of patients with plasma eicosanoid data 
(n=96) (Panel A) and patients with urine metabolite data (n=112) (Panel B) were used 
for any analysis regarding these metabolites. CAD=coronary artery disease, EETs= 
epoxyeicosatrienoic acids, UNC=University of North Carolina. 
Panel A 
 
 
Panel B 
 
  
Patients with stable CAD (n=139)
Patients with UNC follow-up (n=127)
Patients with plasma EETs eicosanoid data 
(n=96)
n=12 lost to follow-up
Patients with stable CAD (n=139)
Patients with UNC follow-up 
(n=127)
Patients with urine prostaglandin
metabolite data (n=112)
Patients taking aspirin (n=109)
n=12 lost to follow up
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Figure 2. Baseline eicosanoid biomarker level tertiles and subsequent risk for MACE by 
Kaplan-Meier curves (n=96). The four eicosanoid biomarkers are sum EETs (panel A), 
sum EETs + DHETs (panel B), 14, 15-EET:DHET ratio (panel C), and 20-HETE (panel 
D). EETs=epoxyeicosatrienoic acids, DHETS=dihydroxyeicosatrienoic acids, 20-
HETE=20-hydroxyeicosatetreanoic acid. Red=lowest tertile, blue=middle tertile, 
green=highest tertile.  
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Figure 3. Baseline urine prostaglandin metabolite level tertiles and subsequent risk for 
MACE by Kaplan-Meier curves (n=112). The urine prostaglandin metabolites are TxA2-
M (panel A) and PGI2-M (panel B). TxA2-M (11-dehydro-thromboxane B2) is the stable 
urine metabolite of thromboxane (TxA2). PGI2-M (2,3-dinor-6-keto-prostaglandin F1 
alpha) is the stable urine metabolite of prostacyclin (PGI2). Red=lowest tertile, 
blue=middle tertile, green=highest tertile.  
A.       B. 
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